Showing 1 - 8 results of 8 for search 'Russel Burge', query time: 0.02s
Refine Results
-
1
-
2
-
3
Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clini... by Andrew Blauvelt, Mark Lomaga, Russel Burge, Baojin Zhu, Wei Shen, David Shrom, Martin Dossenbach, Andreas Pinter
Published 2020-02-01
Article -
4
-
5
Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program by Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola
Published 2023-07-01
Article -
6
Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses by April W. Armstrong, Emily Edson-Heredia, April N. Naegeli, Russel Burge, Jiat-Ling Poon, Milena Anatchkova, Luna Sun, Baojin Zhu, Kathleen W. Wyrwich
Published 2020-07-01
Article -
7
Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)... by Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong
Published 2023-06-01
Article -
8
Disease response and patient-reported outcomes among initiators of ixekizumab by Mona Shahriari, Ryan W. Harrison, Russel Burge, Chen-Yen Lin, William N. Malatestinic, Orin M. Goldblum, Robert R. McLean, Margaux M. Crabtree, Jacqueline O’Brien, Elsie L. Grace, Mwangi J. Murage
Published 2022-04-01
Article